Document is current
Any future updates will be listed below
-
Authors
Tariot, Pierre N.
Boada, Mercè
Lanctôt, Krista L.
Hahn-Pedersen, Julie
Dabbous, Firas
Udayachalerm, Sariya
Raket, Lars Lau
Halchenko, Yuliya
Michalak, Wojciech
Weidner, Wendy
Cummings, Jeffrey
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 31 August 2023
Accepted: 26 January 2024
First Online: 15 February 2024
Declarations
:
: The ethics approval and consent were waived for this study.
: Not applicable.
: KLL reports consulting fees from BioXcel Therapeutics, Bright Minds, Cerevel Therapeutics, Eisai Co. Ltd, Exciva, ICG Pharma, Jazz Pharmaceuticals, Kondor Pharma, H Lundbeck A/S, Merck, Novo Nordisk, Praxis Therapeutics, and Sumitomo Pharma Co. Ltd. LLR is an employee of Eli Lilly and Company. JC has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Bristol-Myers Squib, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/EQT, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. FD, SU, and YH are employees of Evidera by PPD, part of Thermo Fisher Scientific.
